The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1457
ISSUE1457
December 8, 2014
Invokamet and Xigduo XR - Two New Combinations for Type 2 Diabetes
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Invokamet and Xigduo XR - Two New Combinations for Type 2 Diabetes
December 8, 2014 (Issue: 1457)
The FDA has approved fixed-dose combinations of
metformin with either canagliflozin (Invokamet) or
dapagliflozin (Xigduo XR) for treatment of patients
with type 2 diabetes not adequately controlled
with any one of these drugs, or in those...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.